Can-Fite's CF602 Erectile Dysfunction Treatment Receives Notice of Patent Allowance in Brazil

Stock Information for Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Can-Fite Biopharma Ltd American Depositary Shares each representing two (2)

Can-Fite Granted Brazilian Patent for Treatment of Sexual Dysfunction
Can-Fite Announces Reverse Split of its Ordinary Shares and ADS Ratio Change
Can-Fite Provides Update on Clinical and Financial Status
Can-Fite's Latest Developments of its Advanced Stage Drug Pipeline will be Presented at Noble Capital Markets 21st Annual Emerging Growth Equity Conference
Can-Fite to Advance New Veterinary Partnership Opportunities for Namodenoson at the BioFIT 2025 Conference
Can-Fite: 9-Year Survival with Complete Cure in an Advanced Liver Cancer Patient Treated with Namodenoson
Can-Fite Reports Complete Resolution of Esophageal Varices in Decompensated Cirrhosis Patient Treated with Namodenoson
Can-Fite Reports H1 2025 Financial Results and Clinical Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.